Based in Ringwood, Hampshire and with an office in California, Sirigen employs 15 people and has developed technology that improves the diagnostics of clinical tests.
Enterprise Capital Funds formed the core of Sirigen’s £10m funding with an initial investment in 2008 from Seraphim Capital (an ECF) and co-investment in subsequent rounds from IQ Capital (another ECF). Other investors in the business included Oxford Capital, YFM and NESTA.
This funding enabled Sirigen to launch the product and start sales while investors also provided strategic direction to the business. Two large commercial contracts followed and the company was successfully sold in September 2012 to Becton Dickinson for a significant undisclosed sum, generating up to a 4x return to investors.
Total investment in Sirigen by ECFs was £4.6m